Archived Monthly Oncology Tumor Boards: Uveal Melanoma: Treatment of Metastatic Disease
The management of metastatic uveal melanoma still presents a major clinical challenge, and it is important for healthcare providers to be aware of the most current recommendations by the NCCN Panel.
Category
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Relapsed/Refractory Mantle Cell Lymphoma
Clinicians are challenged to remain up-to-date about the treatment advances that will enable them to make informed decisions to optimize the clinical outcome of patients with relapsed/refractory disease.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Neoadjuvant and Adjuvant Therapy for Patients with Resectable Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Clinicians need to know the nuances of using neoadjuvant and adjuvant targeted therapy and immunotherapy to improve outcomes for their patients with resected early-stage and locally advanced NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Advances in Systemic Treatment of Metastatic Cutaneous Melanoma
The rapidly evolving treatment landscape for metastatic cutaneous melanoma is reflected in the new update of the NCCN Guidelines for Cutaneous Melanoma. Being familiar with the most current recommendations by the NCCN Panel will help clinicians in their multidisciplinary collaborations and to better support their patients.
Category
  • Melanoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Treatment of Deficient Mismatch Repair or Microsatellite Instability-High (dMMR/MSI-H) Colorectal Cancer
As the clinical understanding of biomarkers in colorectal cancer has deepened, it has become increasingly clear that deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) colorectal cancer should be treated differently from proficient mismatch repair or microsatellite stable (pMMR/MSS) disease in order to reach the best possible outcomes for patients.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Thyroid Carcinomas
Differentiated thyroid cancers have an excellent prognosis with appropriate treatment, and education in optimal management will help guide treatment decisions. For cases of thyroid cancer that require more aggressive treatment, knowledge of the most current treatment approaches can help clinicians give their patients a chance at the best possible outcome.
Category
  • Thyroid Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Identification and Management of Immuno-Oncology Targeted Therapy-Related Adverse Events in Renal Cell Carcinoma
The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving as new data continue to emerge for novel therapy options. As new immune checkpoint inhibitor (ICI)-based combinations continue to be developed, it is critical for clinicians to recognize and effectively manage immune-related adverse events associated with the ICIs in RCC to ensure maximum benefits from the treatment.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Recurrent/Metastatic Cervical Cancer and Neuroendocrine Carcinoma of the Cervix
The management of cervical cancer specific to histology, stage, and setting has changed tremendously and a review of new/latest data is important and helpful for the practitioners in treatment decision-making. Clinicians can benefit from continued education on comparing treatment options to best manage different histological types of cervical cancer.
Category
  • Cervical Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Management of Advanced Ovarian Cancer
Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation